Corporate Presentation
January 2022
A LEADING Gene Therapy BIOTECHNOLOGY COMPANY
GENSIGHT-BIOLOGICS.COM
Disclaimer
This document contains forward-looking statements and estimates made by the GenSight Biologics S.A. (the "Company"), including with respect to the anticipated future performance of the Company, its subsidiaries and affiliates, and the market in which they operate. They include all matters that are not historical facts. These forward-looking statements can be identified by the use of forward-looking terminology including the terms "developments," "estimates," "expects," "intends," "may," "milestones," "potential," "value," "time to market," "targeting," "on track," "planned," "will," "move to," or other variations or comparable terminology, or by discussions of strategy and funding, as well as the Company's, its subsidiaries' and affiliates' technology, and are based on financial and non-financial information, including projections as to the future regulatory situation and other information and assumptions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may
depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of the Company, its subsidiaries and affiliates or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward-looking statements, forecasts and estimates only speak as of the date of this forward-looking statement, and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. The Company, its subsidiaries and affiliates disclaim any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any events, or changes in conditions or circumstances on which any such statement, forecast or estimate is based.
2 January 2022 - non confidential
Investment Case - Transitioning from R&D to Commercial Organization
1
2
3
4
5
Late-stage Biotech
company
Seasoned
management team /
Potential NASDAQ
Listing
LUMEVOQ®
Strong clinical data in
LHON
H1 2023 LUMEVOQ®
European launch
Cutting hedge optogenetics in Retinitis Pigmentosa
Public company founded in 2012 dedicated to developing and commercializing gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
Euronext Listed SIGHT / €265m Market Cap / Avg. 30-day Daily volume: 0.5% of O/S
Management team with strong and highly relevant Biotech experience in R&D and commercialization
Solid investor base of Healthcare specialist investors, including US based investors. Contemplating potential secondary NASDAQ listing
LUMEVOQ® completed 3 Phase III studies in Leber Hereditary Optic Neuropathy (ND4 LHON), a rare and highly debilitating genetic ophthalmic disease leading to sudden loss of central vision and affecting c. 1,200 - 1,500 new patients / year in Europe and the US
Dedicated team in place to accelerate/optimize LUMEVOQ® access in key European territories Available in France through ATU at €700,000 for a bilateral injection
EU regulatory review ongoing - on track for potential approval in Q4 2022 and launch in Q1 2023 Ongoing discussion with US FDA to confirm regulatory timeline
GS030 outstanding early findings reporting blind patients to precisely identify objects (published in Nature Medicine in May 21)
Extension cohort currently being recruited
3 January 2022 - non confidential
Seasoned Executive Team
Bernard Gilly
Chief Executive Officer
PIXIUM VISION (Since 2011) FOVEA PHARMA (2005-2009) SOFINNOVA PARTNERS (2000-2005) TRANSGENE (1992-2000)
Ph.D. in biology and bio-economics
Thomas Gidoin
Chief Financial Officer
DBV TECHNOLOGIES (2012-2015) IPSEN (2008-2011)
ERNST & YOUNG (2007-2008)
Magali Taiel
Chief Medical Officer
ProQR THERAPEUTICS (2016-2018)
ELI LILLY (2004-2016)
PFIZER (2001-2004)
SERVIER (1999-2001)
M.D., Board-certified ophthalmologist
Catherine Cancian
VP of Pharmaceutical Operations
GENETHON (2015-2017)
SANOFI PASTEUR (1998-2014)
4 January 2022 - non confidential
Julio Benedicto
VP of Marketing
IMS CONSULTING (2011-2017) BOOZ & COMPANY (2010-2011) MONITOR GROUP (1994-2009)
Marie-Claude Holtz
VP of Quality
EXELTIS SANTE (2016-2019)
PFIZER (2015-2016)
ABBVIE (2014-2015)
GALDERMA (2012-2013)
LABORATOIRE LAFON (TEVA) (1993-2012)
Pharm.D.
Leigh Shaw
VP of Regulatory Affairs
UNITED NEUROSCIENCE (2017-2020) NIGHTSTARX (2015-2017)
GREGORY FRYER ASSOCIATES (2005-2015) HUNTINGDON LIFE SCIENCES (2002-2005) CANTAB PHARMACEUTICALS (1995-2001)
Pipeline: solid and advanced product portfolio in ophthalmic Gene Therapy
MTS Platform
LHON ND4 (EU)
EMA Orphan Drug Designation
LHON ND4 (US)
FDA Orphan Drug Designation
GS011 LHON ND1
New Undisclosed
Optogenetics
GS030 | Retinitis Pigmentosa (RP) |
EMA & FDA Orphan Drug Designation |
GS030 | Dry AMD & |
Geographic Atrophy | |
Expected | |||||
Preclinical | Phase I / II | Phase III | Registration | Approval | Market Opportunity |
End 2022 | ~ 400 new patients per year | ||||
~ 600 new patients per year | |||||
~ 100 new patients per year | |||||
~ 1,500 new patients per year |
2024 | ~ 15-20,000 new patients per year | |
2024 | ~ 350-400,000 new patients per year |
5 January 2022 - non confidential
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Gensight Biologics SA published this content on 20 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 January 2022 09:35:47 UTC.